BioSpace News Archive

Genetown

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Inhibikase Therapeutics, Inc. is evaluating new molecules with multiple mechanisms of action for c-Abl inhibition.

August 21, 2023
·
7 min read
Biotech Beach

Introducing NeoMab™: GemPharmatech’s Innovative Antibody Gene Humanized Mouse Model

GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation.

August 21, 2023
·
8 min read
FDA

FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants

Today, the U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

August 21, 2023
·
4 min read
Immune Biosolutions - A step closer to the first inhaled antibody treatment for COVID-19

Immune Biosolutions, a Canadian biotech company based in Sherbrooke, reached a new milestone in developing the first inhaled antibody-based treatment against COVID-19.

August 21, 2023
·
3 min read
FDA

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.

August 21, 2023
·
11 min read